No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of drugs that the collaborative partner has the option to license under a separate research program.

+ References

No definition available.

+ Details

Name:	ions_CollaborativeArrangementNumberOfDrugsUnderOptionToLicense
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Cumulative amount of milestone payments, license fees and/or upfront fees received under the collaborative arrangement as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	ions_CumulativePaymentsAndOrFeesReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the cumulative amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	ions_CumulativeUpfrontFeesReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments receivable under the agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivable
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payments to be earned under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ions_MilestonePaymentsToBeEarned
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the minimum amount of payments receivable under the agreement.

+ References

No definition available.

+ Details

Name:	ions_MinimumAmountOfPaymentsReceivable
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the next potential milestone payment to be earned.

+ References

No definition available.

+ Details

Name:	ions_NextPotentialMilestonePayment
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement.

+ References

No definition available.

+ Details

Name:	ions_RevenueRecognitionMultiDeliverableArrangementNumberOfUnitsOfAccounting
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Cumulative amount of previously deferred revenue from upfront fees the Company received that has been amortized into revenue after the Company performed development activities under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_UpfrontFeeAmortizedIntoRevenue
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of upfront fees received during the period under the agreement.

+ References

No definition available.

+ Details

Name:	ions_UpfrontFeeReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=ions_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementDecember2012Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_OncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAmendedJanuary2016Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementJuly2015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_CardiometabolicAndRenalDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_LicenseAndSubstantiveMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - AstraZeneca (Details) $ in Thousands	1 Months Ended	3 Months Ended								7 Months Ended	12 Months Ended
	Jul. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2013 USD ($)	Dec. 31, 2015 USD ($) AccountingUnit	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 Drug	Jan. 31, 2016 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		$ 51,571	$ 49,121	$ 120,428	$ 62,583	$ 84,861	$ 44,063	$ 57,076	$ 28,161		$ 283,703	$ 214,161	$ 147,285
AstraZeneca [Member] \| Collaborations and Licensing Agreements [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned											6,400	27,700	$ 29,100
Deferred revenue		63,300				$ 4,400					$ 63,300	$ 4,400
AstraZeneca [Member] \| Collaborations and Licensing Agreements [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage											2.00%	13.00%	20.00%
AstraZeneca [Member] \| Agreement Entered into in December 2012 [Member] \| Oncology [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		750,000									$ 750,000
Next potential milestone		15,000									15,000
Number of drugs the collaborative partner may license under a separate research program \| Drug														3
Cumulative upfront fees received		31,000									31,000
Revenue earned										$ 11,500
Upfront fee amortized into revenue		11,900									11,900
Deferred revenue		7,600									7,600
Cumulative payments and/or fees received		63,500									63,500
AstraZeneca [Member] \| Agreement Entered into in December 2012 [Member] \| Oncology [Member] \| Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		226,000									226,000
AstraZeneca [Member] \| Agreement Entered into in December 2012 [Member] \| Oncology [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		485,000									485,000
AstraZeneca [Member] \| Amended Agreement Entered into in January 2016 [Member] \| Oncology [Member] \| Subsequent Event [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Milestone payment to be earned															$ 5,000
AstraZeneca [Member] \| Agreement Entered into in July 2015 [Member] \| Cardiometabolic and Renal Diseases [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee received	$ 65,000
Next potential milestone		25,000									$ 25,000
Number of units of accounting \| AccountingUnit											1
AstraZeneca [Member] \| Agreement Entered into in July 2015 [Member] \| Cardiometabolic and Renal Diseases [Member] \| License Fee and Substantive Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Minimum amount of payments receivable		4,000,000									$ 4,000,000
AstraZeneca [Member] \| Agreement Entered into in July 2015 [Member] \| Cardiometabolic and Renal Diseases [Member] \| Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		1,100,000									1,100,000
AstraZeneca [Member] \| Agreement Entered into in July 2015 [Member] \| Cardiometabolic and Renal Diseases [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		$ 2,900,000									$ 2,900,000